123 related articles for article (PubMed ID: 8625367)
1. Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells.
Froesch BA; Stahel RA; Zangemeister-Wittke U
Cancer Immunol Immunother; 1996 Jan; 42(1):55-63. PubMed ID: 8625367
[TBL] [Abstract][Full Text] [Related]
2. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.
Sinkule JA; Rosen ST; Radosevich JA
Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.
King HD; Yurgaitis D; Willner D; Firestone RA; Yang MB; Lasch SJ; Hellström KE; Trail PA
Bioconjug Chem; 1999; 10(2):279-88. PubMed ID: 10077478
[TBL] [Abstract][Full Text] [Related]
5. Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates.
Hebert C; Norris K; Sauk JJ
J Drug Target; 2003 Feb; 11(2):101-7. PubMed ID: 12881196
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody SEN7 recognizes a new epitope on the neural cell adhesion molecule present on small cell lung cancer but not on lymphocytes.
Waibel R; Mannhart M; O'Hara CJ; Brocklehurst C; Zangemeister-Wittke U; Schenker T; Lehmann HP; Weber E; Stahel RA
Cancer Res; 1993 Jun; 53(12):2840-5. PubMed ID: 7684948
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer.
Zangemeister-Wittke U; Collinson AR; Frösch B; Waibel R; Schenker T; Stahel RA
Br J Cancer; 1994 Jan; 69(1):32-9. PubMed ID: 7506925
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
Elbayoumi TA; Torchilin VP
Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
[TBL] [Abstract][Full Text] [Related]
9. Determinants of differential doxorubicin sensitivity between SCLC and NSCLC.
Singhal SS; Wickramarachchi D; Singhal J; Yadav S; Awasthi YC; Awasthi S
FEBS Lett; 2006 Apr; 580(9):2258-64. PubMed ID: 16579994
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages.
Dubowchik GM; Radia S; Mastalerz H; Walker MA; Firestone RA; Dalton King H; Hofstead SJ; Willner D; Lasch SJ; Trail PA
Bioorg Med Chem Lett; 2002 Jun; 12(11):1529-32. PubMed ID: 12031335
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
12. Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma.
Song JX; Li FQ; Cao WL; Jia X; Shi LN; Lu JF; Ma CF; Kong QQ
Target Oncol; 2014 Sep; 9(3):263-72. PubMed ID: 23943313
[TBL] [Abstract][Full Text] [Related]
13. (6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin.
Willner D; Trail PA; Hofstead SJ; King HD; Lasch SJ; Braslawsky GR; Greenfield RS; Kaneko T; Firestone RA
Bioconjug Chem; 1993; 4(6):521-7. PubMed ID: 7508268
[TBL] [Abstract][Full Text] [Related]
14. Modulation of doxorubicin cytotoxicity by ethacrynic acid.
Awasthi S; Singhal SS; He N; Chaubey M; Zimniak P; Srivastava SK; Singh SV; Awasthi YC
Int J Cancer; 1996 Nov; 68(3):333-9. PubMed ID: 8903475
[TBL] [Abstract][Full Text] [Related]
15. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
16. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
[TBL] [Abstract][Full Text] [Related]
17. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity.
Braslawsky GR; Kadow K; Knipe J; McGoff K; Edson M; Kaneko T; Greenfield RS
Cancer Immunol Immunother; 1991; 33(6):367-74. PubMed ID: 1878890
[TBL] [Abstract][Full Text] [Related]
18. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin.
Desrues B; Léna H; Brichory F; Ramée MP; Toujas L; Delaval P; Dazord L
Br J Cancer; 1995 Nov; 72(5):1076-82. PubMed ID: 7577450
[TBL] [Abstract][Full Text] [Related]
20. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker.
Greenfield RS; Kaneko T; Daues A; Edson MA; Fitzgerald KA; Olech LJ; Grattan JA; Spitalny GL; Braslawsky GR
Cancer Res; 1990 Oct; 50(20):6600-7. PubMed ID: 2208122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
